Maintenance of antiangiogenic and antitumor effects by orally active low-dose capecitabine for long-term cancer therapy [Medical Sciences]

Long-term uninterrupted therapy is essential for maximizing clinical benefits of antiangiogenic drugs (AADs) in cancer patients. Unfortunately, nearly all clinically available AADs are delivered to cancer patients using disrupted regimens. We aim to develop lifetime, nontoxic, effective, orally active, and low-cost antiangiogenic and antitumor drugs for treatment of cancer patients....

http://ift.tt/2siXIOQ